Taken together, these results suggest that syntenin could activate ERK1/2 through an integrin/RAS/RAF/MEK/ERK signaling pathway, and ERK1/2 activation was essential for syntenin-induced migration and invasion in breast cancer cells. Here, SDCBP is linked to breast cancer.